Study of Immune Function and Early Biomarkers After Pancreaticoduodenectomy for Pancreatic Head Tumors

What this Trial Is About

Pancreatic adenocarcinoma is a serious condition and may become the second leading cause of cancer-related death in France by 2030. Pancreaticoduodenectomy PD is the standard surgery for tumors in the pancreatic head, but postoperative complications remain common and can worsen patient outcomes. This study investigates how immune system changes after PD relate to severe pancreatic complications and examines whether a specific immune marker, mHLA-DR, can serve as an early warning sign for these complications. Participants will have blood samples taken to analyze mHLA-DR levels at several times before surgery, immediately after surgery, and on postoperative days one through seven. These samples will be processed using flow cytometry in a specialized laboratory to measure mHLA-DR expression on immune cells. This observational study focuses on adults undergoing PD for benign or malignant tumors of the pancreatic head at four centers. During the study, researchers will closely monitor mHLA-DR expression over the first week after surgery. The main outcome is the number of mHLA-DR molecules per monocyte, measured at defined time points from pre-operation to postoperative day seven. This approach aims to improve understanding of immune responses linked to complications like pancreatic fistula and sepsis following PD. Participation includes blood sample collections and follow-up during the early postoperative period to assess immune changes and correlate them with clinical outcomes.

Immunoparalysis After Pancreaticoduodenectomy